Displaying 25 - 36 of 37
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
6

Echosens: Enhancing the management of NAFLD patients with FibroScan-based scores - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Displaying 25 - 36 of 37